Pharma&

What Pharma& does

Pharma& (legal entity: pharmaand GmbH) is a privately owned specialty pharmaceutical company founded in 2017 by Frank Rotmann and Elmar Zagler, headquartered in Vienna, Austria, with operations across 15 countries. The company acquires worldwide rights to high-need specialty therapeutics that would otherwise be discontinued by originators, preserving patient access to essential medicines across hematology, oncology, psychiatry, urology, gastroenterology, cardiovascular, and pneumology. Its portfolio of 11+ acquired branded products includes Pegasys® (peginterferon alfa-2a, acquired from Roche in 2021), Rubraca® (rucaparib, 2023), Farydak® (panobinostat, from Secura Bio 2022), Levact®/bendamustine (from Astellas 2022), and pipeline asset satraplatin (from Dayton Therapeutics 2024).

The company operates as a fully integrated pharmaceutical manufacturer through its wholly-owned API subsidiary Loba biotech GmbH in Fischamend, Austria (2,500 sqm production, 1,300 sqm QC laboratory, 18-stage API purification) and the newly opened 7,000 sqm pharma& Scheibbs secondary packaging facility (GMP-certified September 2025). Distribution occurs through wholly-owned sales subsidiaries across Europe, the US, and Canada, supplemented by US joint ventures with Heritage Biologics (home-infusion specialty pharmacy, 50% stake) and Summit SD, an exclusive Tolmar promotional partnership for Rubraca in U.S. mCRPC, and channel partners including Accelera Pharma Canada and GHN Pharma Nordic.

Pharma& generates revenue primarily through direct sales of acquired specialty pharmaceutical products to healthcare providers in Europe and the United States, supplemented by distribution partnerships globally. Its go-to-market is sales-led with field promotion in Europe and the US for approved indications, and the company runs a Patient Assistance Program for eligible U.S. patients on Pegasys. The business is transitioning from pure mature-asset acquisition toward clinical development, evidenced by the SAMOA Phase 1/2 trial for satraplatin in primary CNS lymphoma initiated in 2025. With nearly 400 employees and no disclosed external funding, the company appears to fund growth and acquisitions from operating cash flow.

Name

Pharma&

Legal name

pharmaand GmbH

Website

https://pharmaand.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Pharma& is a privately owned, Vienna-based specialty pharmaceutical company that acquires worldwide rights to high-need therapeutics that larger manufacturers discontinue, preserving access for patients in hematology, oncology, and other specialty areas across 15 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Specialty pharmaceuticals
• Branded medicines
• Pharmaceutical manufacturing
• Oncology therapeutics
• Hematology treatments

Headquarters

HQ city

Cham

HQ country

Switzerland

HQ region

Europe

Offices17 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Specialty Pharmaceutical Product Sales: pharma& generates revenue through acquiring worldwide rights to high-need specialty therapeutics and commercializing them globally. The company focuses on preserving availability and further developing essential medicines including treatments in hematology and oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Pharma& acquires worldwide rights to high-need specialty therapeutics and proven essential medicines that would otherwise be discontinued by their original manufacturers, then commercializes and further develops them through a fully integrated organization. The portfolio spans 11 acquired brands across oncology, hematology, urology, gastroenterology, psychiatry, and cardiovascular/pneumology. The company operates vertically integrated API manufacturing (Loba biotech GmbH) and secondary packaging (pharma& Scheibbs) facilities in Austria to ensure stable supply.

Product overview

Pharma& is a privately owned global pharmaceutical company dedicated to preserving the availability and fostering the further development of essential medicines. The company's product portfolio consists of 11 acquired branded medicines spanning multiple therapeutic areas: psychiatry (Anafranil®), urology (Androskat®, Dridase®, Emselex®), gastroenterology (Asacol®, Faktu®), cardiovascular/pneumology (Euphyllin®), hematology (Farydak®, Pegasys®), and oncology (Levact®, Rubraca®). The portfolio includes both established off-patent specialty medicines and high-value acquisitions such as Pegasys® (peginterferon alfa-2a) acquired from Roche in 2021 and Rubraca® (rucaparib) acquired in 2023. Pharma& operates as a fully integrated organization with in-house manufacturing capabilities through its wholly-owned Loba biotech GmbH subsidiary (API production) and the pharma& Scheibbs secondary packaging facility. The development pipeline includes satraplatin in the SAMOA Phase 1/2 trial for PCNSL. The company distributes medicines globally through subsidiaries across 15 countries and joint ventures including Heritage Biologics and Summit SD in the U.S.

Differentiator

Problem solved

Functional benefit

Brands

• pharma& Scheibbs: Secondary packaging facility in Scheibbs, Austria (7,000 sqm production facility)
• Loba biotech GmbH

Products and services

• Pegasys® (peginterferon alfa-2a) An immunostimulant and hematology treatment for myeloproliferative neoplasms (MPNs) including polycythemia vera (PV) and essential thrombocythemia (ET). Acquired from Roche in February 2021.
• Rubraca® (rucaparib) A PARP inhibitor oncology medicine for the treatment of ovarian cancer and metastatic castration-resistant prostate cancer (mCRPC), acquired in 2023.
• Levact® (bendamustine) An oncology treatment medicine acquired from Astellas in December 2021, securing long-term access for patients benefiting from this established therapy.
• Farydak® (panobinostat) A hematology medicine for the treatment of multiple myeloma, acquired from Secura Bio in October 2022.
• Anafranil® (clomipramine hydrochloride) A psychiatric disorder treatment medicine in Pharma&'s specialty care portfolio.
• Androskat® (papaverine hydrochloride/phentolamine mesylate) A urology treatment medicine in Pharma&'s portfolio of essential specialty care medicines.
• Asacol® (mesalazine) A gastroenterology treatment medicine for inflammatory bowel conditions, part of Pharma&'s specialty care portfolio.
• Dridase® (oxybutynin hydrochloride) A urology medicine included in Pharma&'s portfolio of essential specialty care treatments.
• Emselex® (darifenacin hydrobromide) A urology medicine in Pharma&'s specialty care portfolio, indicated for overactive bladder conditions.
• Euphyllin® (theophylline anhydrous) A cardiovascular and pneumology treatment for respiratory conditions, part of Pharma&'s essential medicines portfolio.
• Faktu® (policresulen cinchocaine hydrochloride) An anorectal disorder treatment medicine in Pharma&'s specialty care portfolio.
• Satraplatin An oral platinum-based chemotherapy candidate being developed for relapsed or refractory primary central nervous system lymphoma (PCNSL), with potential to be the world's first approved orally administered precision platinum therapy. Currently in the SAMOA Phase 1/2 clinical trial.
• Loba biotech GmbH (API Manufacturing) A wholly-owned GMP-certified manufacturing plant producing the active pharmaceutical ingredient (API) for peginterferon alfa-2a, featuring a 2,500-square-meter production facility and 1,300-square-meter quality control laboratory in Fischamend, Austria.
• pharma& Scheibbs (Secondary Packaging) A 7,000-square-meter secondary packaging facility in Scheibbs, Austria, providing scalable packaging solutions to support efficiencies across Pharma&'s portfolio.

Quantifiable outcome

• 10+ high-need specialty therapeutics acquired and integrated since 2018

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Tolmar, Inc.coreGTM or Marketing Partner · 24 September 2024Exclusive promotional agreement to promote Rubraca® (rucaparib) in the U.S. for the treatment of metastatic castration-resistant prostate cancer.
• Dayton TherapeuticscoreTechnology or Integration · 17 January 2024Acquired global rights to satraplatin, an oral platinum therapy with potential for CNS lymphoma treatment.
• Shilpa Medicare Ltd. / Zatortia Holdings Ltd.coreTechnology or Integration · 19 April 2021Acquired 100% of shares of LOBA Feinchemie GmbH through share purchase agreement with Zatortia Holdings Ltd., subsidiary of Shilpa Medicare Ltd., India. Enables vertical integration of API production.
• F. Hoffmann-La Roche Ltd.coreTechnology or Integration · 18 February 2021Acquired worldwide rights to Pegasys® (Peginterferon alfa 2a), excluding China and Japan, securing long-term access and supply for patients benefiting from this therapy option.
• Heritage Biologics, LLCcoreStrategic or Co-development PartnerJoint venture with Heritage Biologics, a home-infusion specialty pharmacy specializing in rare and chronic diseases. Heritage Biologics offers the world's first pharmacy patient experience program and value-based healthcare solutions. pharma& acquired 50% of shares through its wholly-owned subsidiary pharma& U.S. Inc.
• Summit SD, LLCcoreStrategic or Co-development PartnerJoint venture partner supporting distribution and provision of patient support services within the U.S. market.
• Dewact Labs GmbHminorStrategic or Co-development PartnerJoint venture partner in Germany for pharmaceutical operations.
• Accelera Pharma Canada Inc.minorChannel Partner/ Reseller/ DistributorPartner for Pegasys® distribution in Canada alongside pharmaand GmbH.
• GHN Pharma Nordic ABminorChannel Partner/ Reseller/ DistributorCollaboration extension and expansion announced in January 2024.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Advanz Pharma: European-headquartered specialty pharma that acquires mature, niche and complex medicines from big pharma and drives them through regulatory and commercial revitalization. Closely mirrors Pharma&'s 'breathe new life into proven medicines' acquisition-led model and therapeutic mix.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with a portfolio of mature, niche branded products (often legacy hospital/specialty care assets) and a history of acquiring divested big-pharma brands. Highly comparable in business model — focusing on off-patent or de-prioritized specialty therapeutics.
• Aspen Pharmacare Holdings: Global specialty pharma that has grown largely through acquisition of branded and off-patent product portfolios from multinational pharma companies. Highly comparable acquisition-driven, portfolio-stewardship model with similar focus on essential mature medicines.
• Recordati S.p.A. European specialty pharma group with a strong focus on niche and rare disease products across multiple therapeutic areas. Comparable in its emphasis on specialty care therapeutics and selective acquisitions to expand its branded specialty portfolio.
• Endo International: Specialty pharmaceutical company focused on branded and generic specialty therapeutics, including mature and de-prioritized brands. Comparable portfolio-management model focused on maintaining supply and value of established specialty assets.
• Stada Arzneimittel AG: European-headquartered specialty and generics pharma that has grown substantially via acquisitions of mature branded portfolios. Comparable in acquiring off-patent and deprioritized specialty brands and operating a broad European + emerging markets footprint.
• Almirall S.A. European specialty pharma focused on dermatology and other specialty therapeutic areas, with selective acquisitions of established brands. Comparable niche/specialty focus and European operational base to Pharma&'s portfolio.
• Amneal Pharmaceuticals: U.S. specialty and generics pharma with a broad portfolio including complex specialty therapeutics and biologics. Comparable mix of branded specialty products and supply-chain integration via internal manufacturing.

Broad incumbents

• Bausch Health Companies: Diversified specialty pharma with broad branded specialty care franchises including oncology and ophthalmology. Overlaps with Pharma& on branded specialty therapeutics but operates at much larger scale and broader portfolio scope.

Emerging players

• Lupin Pharmaceuticals: India-headquartered specialty/generics pharma with growing branded specialty footprint in the U.S. and Europe. Comparable in pursuing specialty therapeutic expansion and global manufacturing, though with a heavier generics tilt than Pharma&.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmaand

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma&